A study by researchers at Columbia University Vagelos College of Physicians and Surgeons has found that new cutting-edge ...
FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027Positions lonvo-z to be the world’s first in vivo ...
Phase 3 HAELO data showed an 87% reduction in monthly attack rates with Ionvoguran ziclumeran, with a PDUFA target date of March 10, 2027.
Researchers developed a compact gene activation tool that could overcome the limitations of existing CRISPR-based tools. The ...
Exegenesis Bio et Modalis Therapeutics Corporation ont annoncé la signature d'un accord de collaboration de recherche et de licence pour faire progresser le MDL-201, un candidat ...
What can pooled CRISPR screening and protein‑level readouts reveal that transcriptomics alone can't? Explore how single‑cell ...
Exegenesis Bio and Modalis Therapeutics Corporation (TOKYO: 4883; "Modalis") today announced that they have signed a research collaboration and license agreement to advance MDL-201, an innovative ...
A study by researchers at Columbia University Vagelos College of Physicians and Surgeons has found that new cutting-edge ...
ARK Invest sold $28.6M of Alphabet stock while buying Meta Platforms and biotech shares after Meta unveiled its AI agent Muse ...
Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.
New cutting-edge techniques can accurately edit genes in human embryos—giving scientists indispensable tools for ...
Intellia Therapeutics (NTLA) stock gains on FDA priority review for lonvo-z, a gene editing therapy for a rare condition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results